Scalper1 News
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market today. The biotech tested obeticholic acid on non-alcoholic fatty liver disease, for which there is no current approved treatment. The drug stopped liver scarring in 46% of patients vs. 21% taking a Scalper1 News
Scalper1 News